Clinical Trials

Below is a list of early phase clinical trials that may recruit from many different cancer diseases. To find out more about a particular clinical trial, click on the “study Information link” for the trial. Once you are in the study specific page, there is a link to contact the study team.

 

Early Phase/Multi Tumor Trials

 

  • STUDY17022

    First in Human, Phase 1/1b, Open label, Multicenter Study of Bifunctional EGFR/TGF ß Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR Driven Advanced Solid Tumors

    The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.

    Study Information


  • STUDY21565

    A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor (Endometrial cohort enrolling 2nd and 3rd line patients.)

    To assess safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s). To assess pharmacokinetic (PK) profile of study drug(s) To assess efficacy (objective response rate [ORR], best overall response [BOR], disease control rate [DCR], clinical benefit rate [CBR], progression-free survival [PFS], overall survival [OS], and duration of response [DOR]) of E7386 in combination with other anticancer drug(s) (Revised per Amendment 06)

    Study Information


  • STUDY21781

    A Phase 1b Dose Escalation Study of AV-380 in Combination with Chemotherapy or Immunotherapy in Cancer Patients with Elevated GDF-15 Levels Colorectal Cancer, NSCLC, Pancreatic Cancer

    To refine the dose and schedule of AV-380 and establish its adverse event (AE), pharmacokinetic (PK), and pharmacodynamic (PD) profile in metastatic cancer patients with cachexia and elevated GDF-15, receiving SoC chemotherapy for metastatic cancer

    Study Information


  • STUDY23202

    A Phase 2a Study with Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Tumors

    To confirm a recommended phase 2 dose (RP2D) of FF-10832 (Gemcitabine Liposome Injection) given intravenously Day 1 of a 21-day cycle, in combination with 200 mg pembrolizumab given intravenously Day 1 of the same 21-day cycle, for treatment of advanced solid tumors; To obtain a preliminary estimate of efficacy of FF-10832 monotherapy in expansion cohorts of patients with urothelial cancer (UC) and on-small cell lung cancer (NSCLC);To obtain a preliminary estimate of efficacy of the combination in expansion cohorts of patients with UC and NSCLC.

    Study Information


  • STUDY23589

    A Phase 1 Open Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications

    To assess the efficacy of ABBV-400 in each solid tumor indication, including advanced or metastatic HCC, BTC, PDAC, ESCC, TNBC, HR+/HER2- BC and HNSCC. To characterize the safety and tolerability of ABBV-400 as monotherapy in advanced or metastatic HCC, BTC, PDAC, ESCC, TNBC, HR+/HER2- BC, and HNSCC.

    Study Information